Aim: To evaluate the efficacy of direct-acting antivirals (DAAs) in Kanto Rosai Hospital.
Methods: All patients with hepatitis C virus (HCV) who underwent DAA prescription were enrolled in this study. The present study was a single center retrospective analysis using patients infected with HCV genotype 1 or 2. Resistance analysis was performed by using direct sequencing and cycleave PCR in genotype 1 patients treated with interferon (IFN)-free DAA. The primary endpoint was sustained virologic response at 12 wk after therapy (SVR12).
Results: A total of 117 patients participated in the study, including 135 with genotype 1 and 42 with genotype 2. Of the 135 patients with genotype 1, 16 received protease inhibitor + IFN + ribavirin and all achieved SVR. Of the 119 patients who received IFN-free DAA (in different combinations), 102 achieved SVR and 9 failed (7/9 were on daclatasvir/asunaprevir and 2/9 on ledipasvir/sofosbuvir). Efficacy analysis was done only for 43 patients who received daclatasvir/asunaprevir. From this analysis, Y93 resistance-associated substitutions were significantly correlated with SVR.
Conclusion: The SVR rate was 98% for genotype 1 and 100% for genotype 2. However, caution is needed for HCV NS5A resistance-associated substitutions that are selected by HCV NS5A inhibitors because cerebrovascular adverse events are induced by some DAA drugs.
Keywords: Direct-acting antivirals; Hepatitis C; Resistance-associated substitutions; Sustained viral response.
Conflict of interest statement
Conflict-of-interest statement: The authors declare no potential conflict of interest.
Randomized Trial of Daclatasvir and Asunaprevir With or Without PegIFN/RBV for Hepatitis C Virus Genotype 1 Null RespondersAS Lok et al. J Hepatol 60 (3), 490-9. PMID 24444658. - Clinical TrialIn genotype 1 null responders, daclatasvir plus twice-daily asunaprevir DUAL therapy is effective for most genotype 1b patients, and daclatasvir, asunaprevir, and PegIFN/ …
Efficacy of an Interferon- And Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 InfectionGT Everson et al. Gastroenterology 146 (2), 420-9. PMID 24184132. - Clinical TrialIn a phase 2a study, the all-oral, interferon-free, and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 was well tolerated and achieved high rates of S …
High Efficacy of Resistance-Guided Retreatment of HCV Patients Failing NS5A Inhibitors in the Real WorldAB Pérez et al. J Hepatol 71 (5), 876-888. PMID 31279901.In our study, we show how resistance-guided retreatment in conjunction with an interpreted report allows patients to achieve SVR rates close to 90%. We hypothesize that S …
Treatment of Hepatitis C Virus Genotype 3-infectionS Pol et al. Liver Int 34 Suppl 1, 18-23. PMID 24373074. - ReviewThe treatment of hepatitis C virus (HCV) infection with pegylated interferon (PEG-IFN) alfa and ribavirin (800 mg daily) (RBV) is the standard of care (SOC) for hepatitis …
Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected PatientsMW Hull et al. Curr Infect Dis Rep 18 (7), 22. PMID 27357277. - ReviewA number of DAA combinations have completed clinical trials and are available for use. Current combinations are often genotype-specific, and combine HCV protease inhibito …
- Ray Kim W. Global epidemiology and burden of hepatitis C. Microbes Infect. 2002;4:1219–1225. - PubMed
- Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17:107–115. - PubMed
- Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Otani S. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051–1055. - PubMed
- Tanaka H, Imai Y, Hiramatsu N, Ito Y, Imanaka K, Oshita M, Hijioka T, Katayama K, Yabuuchi I, Yoshihara H, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med. 2008;148:820–826. - PubMed